Bio-Path Holdings, Inc. (NASDAQ: BPTH) is focused on developing therapeutic products that use its proprietary liposomal delivery technology, which is designed to systemically distribute nucleic acid drugs throughout the human body via a simple intravenous infusion. The company’s initial focus is on cancer, and its lead product candidate, Liposomal Grb-2, will soon start a phase II study for blood cancers. The company’s second drug candidate, also a liposomal antisense drug, is ready for the clinic, where it will be evaluated in lymphoma and solid tumors. For more information, visit the company’s website at www.biopathholdings.com.